Alicia Noriega Tato

  • IBBTEC. C/ Albert Einstein, 22. 39011 Santander
  • alicia.noriegatato@unican.es
  • 942 206 799 ext. 25907
  • Spatial Regulation of Ras-ERK Signals in Cancer
  • Cancer
  • Department of Cell & Molecular Signalling

Alicia received her first degree in Chemistry from the University of Cantabria (Spain,2005). After a short period working in a private chemical company, she got interested in the biomedical research area obtaining a 2 years Advanced Vocational Qualification in Laboratory Analysis (Cantabria, 2009). awaredwith the best qualification of laboratory field in Cantabria the fact that gave her the opportunity to get a 2 years position working as a young technician at the Institute of Dairy Products of Asturias (IP, Baltasar Mayo,CSIC, Asturias).

Then, she worked as technician Cell Cycle, Stem Cell Fate and Cancer Group (IP, Alberto Gandarrillas, IDIVAL, Cantabria) during 3 years and  another year working in Tissue Engineering Group (IP, Jose Carlos Rodríguez rey, IDIVAL, Cantabria).

While working in biomedical research area she continued improving her CV obtaining a 2 years degree in Clinical and Biomedical Laboratory (Cantabria, 2017).

Since 2017, Alicia has been working as a laboratory technician in Spatial regulation of Ras-ERK signals in cancer Group (IP, Berta Casar, IBBTEC, Cantabria).

​Spatial Regulation of Ras-ERK Signals in Cancer


Research lines 

    • Spatial regulation of Ras-ERK signals in physiological processes and in cancer
    • Development of antitumoral drugs targeting protein-protein interactions in the Ras-ERK pathway


Funding

    • "Las interacciones entre proteínas scaffolds y dímeros de ERK como dianas antitumorales". BFU2011-23807. 2012-2015.
    • “Nuevas dianas moleculares en la ruta Ras-ERK: potencial terapéutico en el cáncer de tiroides”. Asociación Española Contra el Cáncer (AECC). GCB141423113. Proyecto coordinado 2014-2019. 
    • Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC). RD/12/0036/0033. 2012-2015.
    • “Proteínas Scaffold como moduladores de la resistencia a inhibidores de la ruta RAS-ERK en melanoma”.  SAF-2015 63638R.  2016-2018.

isciiPiero.png

GRUPO FINANCIADO POR LA RED TEMÁTICA DE INVESTIGACIÓN COOPERATIVA EN CÁNCER DEL ISCIII/FEDER (RD12/0036/0033). 2012-2016  
Grupo incluído en el programa: Molecular Mechanisms in Cancer. Involucrado en el desarrollo de nuevas estratégias terapéuticas para inhibir rutas de señalización pro-tumorales.


Piero Crespo Baraja (IP)

View more

Lorena Agudo Ibáñez

View more

Vincenzo Cappitelli

View more

Dalia de la Fuente Vivas

View more

Rocío García Gómez

View more

Marta Morante Ezquerra

View more

Laura Ruiz Peinado

View more